GlobeNewswire by notified

Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA

Share

Negma Group has converted 80convertible bonds in Oxurion resulting in a EUR 200,000capital increase. This is part of Negma Group’s EUR 30 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel and differentiated back of the eye drug candidate targeting potential market opportunities of over USD 5billion.

Leuven, BELGIUM,Boston, MA, USDecember6, 2022– 07.00 PM CET – In accordance with article 15 of the Belgian Act of May 2, 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions, Oxurion NV (Euronext Brussels: OXUR) (the “Company” or “Oxurion”), announces the below information, following the issuance of 21,008,403 new ordinary shares on December 5, 2022, for a total amount of EUR 200,000, as the result of the conversion of 80 class B convertible bonds, pursuant to the Capital Commitment entered into with Negma Group.

Following completion of the capital increase through the conversion of the convertible bonds, the total number of shares issued by Oxurion amounts to 311,281,644, outstanding ordinary shares carrying voting rights (compared to 290,273,241 outstanding ordinary shares previously). This number will be used as the denominator for the calculation of the percentages of shareholdings.

Therefore, Oxurion publishes the following updated information:

  • Share capital (EUR)
74,906,161.32
  • Total number of securities with voting rights (all ordinary shares)
311,281,644
  • Total number of ordinary shares (= denominator)
311,281,644
  • Number of outstanding, granted rights to subscribe to securities carrying voting rights not yet issued:
  • 719,500 subscription rights (“SRs”) issued on November 20, 2017, entitling their holders to subscribe to a total number of 719,500 securities carrying voting rights (all ordinary shares);
  • 60,000 SRs issued on December 23, 2020, entitling their holders to subscribe to a total number of 60,000 securities carrying voting rights (all ordinary shares);
  • 1,007,250 SRs issued on April 14, 2021, entitling their holders to subscribe to a total number of 1,007,250 securities carrying voting rights (all ordinary shares);
  • 550,000 SRs issued on September 22, 2021, entitling their holders to subscribe to a total number of 550,000 securities carrying voting rights (all ordinary shares);
  • 725,749 SRs issued on December 30, 2021, entitling their holders to subscribe to a total number of 725,749 securities carrying voting rights (all ordinary shares);
  • 580 convertible bonds issued on September 5, 2022, October 21, 2022, and November 28, 2022, entitling their holder (Negma Group) to subscribe to a total number of securities carrying voting rights (all ordinary shares) in accordance with the terms and conditions set forth in the issuance and subscription agreement entered into between the Company and Negma Group on August 26, 2021, and the addendum thereto dated September 2, 2022; and
  • 100 convertible bonds issued on December 20, 2021, entitling their holders (Kreos Capital VI (UK) Limited, Pontifax Medison Finance (Israel) L.P. and Pontifax Medison Finance (Cayman) L.P.) to subscribe to a total number of securities carrying voting rights (all ordinary shares) in accordance with the terms and conditions of these convertible bonds as attached to the Agreement for the provision of a Loan Facility entered into between the Company, Kreos Capital VI (UK) Limited, Pontifax Medison Finance (Israel) L.P. and Pontifax Medison Finance (Cayman) L.P., on November 21, 2021.

END

About Oxurion

Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people, as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders, including the successful development of THR-149, its novel therapeutic for the treatment of DME. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of DME patients showing suboptimal response to anti-VEGF therapy. Oxurion is headquartered in Leuven, Belgium, with corporate operations in Boston, MA. More information is available at www.oxurion.com.

Important information about forward-looking statements

Certain statements in this press release may be considered “forward-looking”. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company’s Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

For further information please contact:

Oxurion NV
Tom Graney
Chief Executive Officer
Tel: +32 16 75 13 10
tom.graney@oxurion.com



Michaël Dillen
Chief Business Officer
Tel: +32 16 75 13 10
michael.dillen@oxurion.com
US
Conway Communications
Beth Kurth
bkurth@conwaycommsir.com





ICR Westwicke
Christopher Brinzey
Tel: +1 617 835 9304
chris.brinzey@westwicke.com



1Press release Oxurion, 06/04/2021 and Press release Oxurion, 02/09/2022

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

CGFNS International Reaffirms Its Commitment to Combatting Fraud in Nurse Credentialing2.2.2023 16:01:58 CET | Press release

PHILADELPHIA, Feb. 02, 2023 (GLOBE NEWSWIRE) -- In the wake of federal charges related to large-scale schemes to sell fake nursing diplomas at some U.S. nursing schools, CGFNS International, a global leader in international credentials evaluation to support health worker mobility, has bolstered its efforts to combat fraud and ensure patient safety through the assessment and authentication of credentials. Leaders at the organization, which has 45 years of experience in evaluating international education credentials for foreign-trained health workers, pointed to the global nursing shortage as a key driver of increased fraud. "CGFNS is actively reviewing whether any of the reports we issued are impacted," said CGFNS President and Chief Executive Officer Dr. Peter Preziosi. "If we find evidence of this, we will move quickly to address it." "An honestly-earned education paired with appropriate clinical experience is a prerequisite for nursing licensure and is absolutely essential to protect

Graid Technology Announces Software Update Targeted at Enhancing Business Continuity for NVMe Deployments2.2.2023 15:00:00 CET | Press release

SupremeRAID™ new high availability feature provides an additional level of business continuity protection coupled with superior overall performance. SANTA CLARA, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Graid Technology, the award-winning data protection provider and developer of the only RAID card to offer customers access to the full performance of NVMe SSDs, is proud to announce its latest software release (V1.3) for SupremeRAID™ SR-1000 and SR-1010. The various enhancements in this release include features and software updates designed to support dual controller high availability along with support for multiple new NVMe SSDs. Among the enhanced features in the new release is a configurable strip size, allowing customers using RAID 0 and RAID 10 to realize even better server performance, a strategic move that continues to position SupremeRAID™ as the performance leader for both random and sequential workloads. "This latest release gives our customers peace of mind knowing that thei

Global Chauffeur Service Blacklane names Cindy Rubbens as Chief People Experience Officer and Gudrun Herrmann as Global Head of Communications2.2.2023 14:45:44 CET | Press release

Rubbens will oversee the continuous scaling of Blacklane while driving growth via learning and development, while Herrmann is tasked with building up an external and internal strategic communications function and co-drive its sustainability efforts. BERLIN, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Global chauffeur service, Blacklane, announced that it has named Cindy Rubbens Chief People Experience Officer (CPXO) and Gudrun Herrmann Global Head of Communications, effective immediately. Both will report to Blacklane CEO and CO-Founder Dr. Jens Wohltorf and will be charged with developing the Talent Attraction and Human Resources as well as Communications respectively during the company’s bid to scale while driving the next phase of growth. In her role as CPXO, Rubbens will support the sustainable development of Blacklane’s crew while the business continues scaling new, industry-leading services and expanding markets. Rubbens will focus on strengthening the Talent Attraction function while assi

Landsbankinn hf.: Financial results of Landsbankinn for 20222.2.2023 14:36:13 CET | Press release

Landsbankinn's net profit in 2022 was ISK 17.0 billion. There was good growth in loans to corporates, ISK 92.0 billion or the equivalent of 10%, having regard for currency changes.Mortgage loans grew by 59.0 billion with demand decreasing in the fourth quarter.ROE in the fourth quarter of 2022 was 8.2%, compared with 10.5% ROE in the same quarter of 2021. ROE in 2022 was 6.3%, despite solid core earnings. The negative impact reducing profitability was mainly a decrease in the fair value of the Bank’s holding in Eyrir Invest hf. The Bank’s target ROE is 10% at a minimum. Operating expenses are stable. Landsbankinn topped the Icelandic Performance Satisfaction Index for banking customers the fourth year in a row. The Bank’s market share in the retail market has never been higher and measures over 40% for the first time. Loans in arrears are at a historic low and loans in arrears were 0.2% at the turn of the year.In 2022, the Bank paid a dividend of ISK 20.5 billion and ISK 14.1 billion i

Centessa Pharmaceuticals Announces Presentation at the SVB Securities Global Biopharma Conference2.2.2023 14:00:00 CET | Press release

BOSTON and LONDON, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company focused on discovering and developing medicines that are transformational for patients, today announced that members of its management team will participate in a fireside chat at the virtual SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023 at 8:00 a.m. ET. A webcast of the fireside chat, as well as an archived recording, will be available under the “Events and Publications” tab on the investor relations section of the Centessa Pharmaceuticals website at https://investors.centessa.com/events-presentations. About Centessa Pharmaceuticals Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients. Our programs span discovery-stage to late-stage development and cover a range of high-value indications. We operate with the conviction that